X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (436) 436
Book Review (36) 36
Publication (16) 16
Newsletter (3) 3
Newspaper Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (319) 319
ofloxacin (273) 273
humans (235) 235
female (136) 136
male (127) 127
levofloxacin (121) 121
ciprofloxacin (106) 106
antibiotics (101) 101
ofloxacin - therapeutic use (101) 101
middle aged (92) 92
adult (89) 89
fluoroquinolones (83) 83
pharmacology & pharmacy (81) 81
aged (75) 75
anti-bacterial agents - therapeutic use (70) 70
ofloxacin - administration & dosage (67) 67
treatment outcome (64) 64
microbiology (59) 59
infectious diseases (57) 57
analysis (56) 56
microbial sensitivity tests (52) 52
ofloxacin - economics (52) 52
environmental sciences (48) 48
ofloxacin - pharmacology (48) 48
drug therapy (47) 47
drug resistance (43) 43
anti-bacterial agents - administration & dosage (41) 41
anti-bacterial agents - pharmacology (40) 40
quinolones (40) 40
adolescent (38) 38
animals (37) 37
anti-infective agents - therapeutic use (37) 37
infections (37) 37
administration, oral (36) 36
anti-bacterial agents - economics (36) 36
drug resistance in microorganisms (36) 36
drugs (34) 34
community-acquired infections - drug therapy (32) 32
prospective studies (32) 32
community-acquired pneumonia (31) 31
drug resistance, bacterial (31) 31
medicine, general & internal (31) 31
pharmaceuticals (31) 31
abridged index medicus (30) 30
anti-infective agents - administration & dosage (30) 30
drug therapy, combination (30) 30
ofloxacin - adverse effects (29) 29
antibacterial agents (28) 28
chemistry, analytical (28) 28
norfloxacin (28) 28
risk factors (28) 28
tuberculosis (27) 27
antimicrobial resistance (26) 26
retrospective studies (26) 26
aged, 80 and over (25) 25
health aspects (25) 25
moxifloxacin (25) 25
pneumonia, bacterial - drug therapy (25) 25
resistance (25) 25
china (24) 24
therapy (24) 24
time factors (24) 24
management (23) 23
medicine & public health (23) 23
methods (23) 23
research (23) 23
efficacy (22) 22
prevalence (22) 22
antimicrobial agents (21) 21
cost-benefit analysis (21) 21
drug costs (21) 21
pneumonia (21) 21
research article (21) 21
toxicology (21) 21
anti-infective agents - pharmacology (20) 20
care and treatment (20) 20
environment (20) 20
medicine (20) 20
susceptibility (20) 20
anti-infective agents - economics (19) 19
ciprofloxacin - therapeutic use (19) 19
double-blind method (19) 19
drug administration schedule (19) 19
erythromycin (19) 19
mycobacterium tuberculosis - drug effects (19) 19
rifampin (19) 19
water pollutants, chemical - analysis (19) 19
antitubercular agents - therapeutic use (18) 18
aquatic environment (18) 18
child (18) 18
epidemiology (18) 18
hospitals (18) 18
liquid chromatography (18) 18
risk assessment (18) 18
adsorption (17) 17
amoxicillin (17) 17
anti-bacterial agents - adverse effects (17) 17
anti-bacterial agents - analysis (17) 17
costs (17) 17
immunology (17) 17
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Therapeutics, ISSN 0149-2918, 2008, Volume 30, Issue 2, pp. 358 - 371
Abstract Background: Macrolide antibiotics and fluoroquinolones are extensively used in the treatment of community-acquired pneumonia (CAP). Objective: This... 
Internal Medicine | Medical Education | costs | macrolides | CAP | levofloxacin | treatment failure | community-acquired pneumonia | claims analysis | resource utilization | UNITED-STATES | ANTIMICROBIAL THERAPY | ADULTS | SEVERITY INDEX | OF-AMERICA GUIDELINES | STREPTOCOCCUS-PNEUMONIAE | EMERGENCY-DEPARTMENT | RESISTANCE | ECONOMIC OUTCOMES | PHARMACOLOGY & PHARMACY | ELDERLY-PATIENTS | Drug Costs | Health Resources - utilization | Hospital Costs | Levofloxacin | Ambulatory Care - utilization | Humans | Middle Aged | Ofloxacin - economics | Ofloxacin - therapeutic use | Male | Pneumonia, Bacterial - economics | Drug Utilization | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Treatment Failure | Adult | Female | Managed Care Programs - utilization | Retrospective Studies | Odds Ratio | Anti-Bacterial Agents - economics | Macrolides - economics | Risk Assessment | Community-Acquired Infections - economics | Risk Factors | Health Resources - economics | Logistic Models | Databases as Topic | Emergency Service, Hospital - economics | Health Care Costs | Cost-Benefit Analysis | Pneumonia, Bacterial - drug therapy | Aged | Ambulatory Care - economics | Macrolides - therapeutic use | Managed Care Programs - economics | Insurance Claim Reporting | Pneumonia | Databases | Utilization | Analysis | Bacterial pneumonia | Medical care | Health care industry | Erythromycin | Medical economics | Antibacterial agents | Medical care, Cost of | Index Medicus
Journal Article
Value in Health, ISSN 1098-3015, 2009, Volume 12, Issue 8, pp. 1135 - 1143
ABSTRACT Objective This study aimed to evaluate the length of stay (LOS), costs, and treatment consistency among patients hospitalized with community-acquired... 
Internal Medicine | cost | treatment outcomes | levofloxacin | length of stay | community-acquired pneumonia | hospital | moxifloxacin | Levofloxacin | Treatment outcomes | Community-acquired pneumonia | Hospital | Moxifloxacin | Cost | Length of stay | CLARITHROMYCIN | CONTROLLED-TRIAL | EFFICACY | SAFETY | ADULTS | ADHERENCE | CARE | AMERICA GUIDELINES | ORAL MOXIFLOXACIN | THERAPY | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | ECONOMICS | Fluoroquinolones | Multivariate Analysis | Confidence Intervals | Injections, Intravenous | Length of Stay - economics | Aza Compounds - therapeutic use | Humans | Ofloxacin - economics | Hospitalization - statistics & numerical data | Ofloxacin - therapeutic use | Diagnosis-Related Groups | Male | Statistics as Topic | Pneumonia, Bacterial - economics | Quinolines - administration & dosage | Quinolines - economics | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Statistics, Nonparametric | Ofloxacin - administration & dosage | Female | Retrospective Studies | Pulmonary Disease, Chronic Obstructive - economics | Length of Stay - statistics & numerical data | Databases, Factual | Anti-Bacterial Agents - economics | Aza Compounds - administration & dosage | Community-Acquired Infections - economics | Anti-Infective Agents - therapeutic use | Logistic Models | Treatment Outcome | Aza Compounds - economics | Propensity Score | Health Care Costs | Anti-Infective Agents - administration & dosage | Anti-Infective Agents - economics | Pneumonia, Bacterial - drug therapy | Aged | Quinolines - therapeutic use | Anti-Bacterial Agents - administration & dosage | Hospitalization - economics | Pulmonary Disease, Chronic Obstructive - drug therapy | Hospital patients | Pneumonia | Bacterial pneumonia | Comparative analysis | Medical care, Cost of | Index Medicus
Journal Article
Gut, ISSN 0017-5749, 11/2010, Volume 59, Issue 11, pp. 1465 - 1470
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 03/2008, Volume 24, Issue 3, pp. 895 - 906
ABSTRACT Objective: Length of stay (LOS) and hospitalization costs were compared among patients admitted for community-acquired pneumonia (CAP) and initially... 
Levofloxacin | Hospitalization | Community-acquired pneumonia | Moxifloxacin | Length of stay | COMMUNITY-ACQUIRED PNEUMONIA | LEVOFLOXACIN | MOXIFLOXACIN | LENGTH OF STAY | HOSPITALIZATION | MEDICINE, RESEARCH & EXPERIMENTAL | MANAGEMENT | hospitalization | PROPENSITY SCORE | ADMINISTRATIVE DATA | GUIDELINES | ADULTS | community-acquired pneumonia | CARE | MEDICINE, GENERAL & INTERNAL | COSTS | levofloxacin | length of stay | OUTCOMES | EPIDEMIOLOGY | moxifloxacin | Fluoroquinolones | United States | Aza Compounds - therapeutic use | Humans | Insurance Claim Review | Middle Aged | Ofloxacin - economics | Ofloxacin - therapeutic use | Aza Compounds - adverse effects | Male | Pneumonia, Bacterial - economics | Quinolines - administration & dosage | Quinolines - economics | Anti-Bacterial Agents - therapeutic use | Ofloxacin - adverse effects | Community-Acquired Infections - drug therapy | Ofloxacin - administration & dosage | Female | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Anti-Bacterial Agents - economics | Length of Stay | Aza Compounds - administration & dosage | Anti-Infective Agents - adverse effects | Comorbidity | Community-Acquired Infections - economics | Anti-Infective Agents - therapeutic use | Treatment Outcome | Aza Compounds - economics | Health Care Costs | Anti-Infective Agents - administration & dosage | Anti-Infective Agents - economics | Pneumonia, Bacterial - drug therapy | Aged | Quinolines - therapeutic use | Infusions, Intravenous | Anti-Bacterial Agents - administration & dosage | Research Design | Quinolines - adverse effects | Hospitalization - economics | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Sexually Transmitted Diseases, ISSN 0148-5717, 12/2007, Volume 34, Issue 12, pp. 960 - 966
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 05/2008, Volume 24, Issue 5, pp. 1279 - 1284
ABSTRACT Objective: This study presents a cost-minimisation analysis of moxifloxacin compared to combination treatment with levofloxacin and ceftriaxone in... 
Levofloxacin | Costs and cost analysis | Pneumonia | Ceftriaxone | Moxifloxacin | Community-acquired infections | COMMUNITY-ACQUIRED INFECTIONS | COSTS AND COST ANALYSIS | LEVOFLOXACIN | MOXIFLOXACIN | PNEUMONIA | CEFTRIAXONE | CLARITHROMYCIN | MEDICINE, RESEARCH & EXPERIMENTAL | POSTMARKETING SURVEILLANCE | costs and cost analysis | EFFICACY | SAFETY | community-acquired infections | ceftriaxone | MEDICINE, GENERAL & INTERNAL | ORAL MOXIFLOXACIN | SEQUENTIAL IV | THERAPY | pneumonia | levofloxacin | moxifloxacin | Fluoroquinolones | Prospective Studies | Follow-Up Studies | Humans | Ofloxacin - economics | Cost of Illness | Male | Pneumonia, Bacterial - economics | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Quinolines - economics | Community-Acquired Infections - drug therapy | Ofloxacin - administration & dosage | Ceftriaxone - administration & dosage | Female | Drug Therapy, Combination | Length of Stay | Severity of Illness Index | Aza Compounds - administration & dosage | Pneumonia, Bacterial - microbiology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Community-Acquired Infections - economics | Ceftriaxone - economics | Treatment Outcome | Aza Compounds - economics | Hospitalization | Cross-Over Studies | Cost-Benefit Analysis | Pneumonia, Bacterial - drug therapy | Infusions, Intravenous | Community-Acquired Infections - microbiology | Index Medicus
Journal Article